ENDPOINTS NEWS7m
Xy­lo­Cor rais­es $67.5M Se­ries B, up­dates piv­otal gene ther­a­py tri­al plans
XyloCor raises $67.5M Series B led by Jeito Capital for XC001 gene therapy trials in cardiac patients. CEO Al Gianchetti says ...
ENDPOINTS NEWS37m
Ver­tex signs in vi­vo gene edit­ing de­liv­ery pact for sick­le cell and tha­lassemia as it looks be­yond Cas­gevy
Vertex partners with Orna Therapeutics to develop in vivo gene editing treatments for sickle cell disease and beta ...
ENDPOINTS NEWS47m
Ken Song's Can­did li­cens­es a T cell en­gager from WuXi Bio
Candid Therapeutics commits $925M for WuXi Biologics' T cell engager rights. CEO Ken Song aims for human trials in 2026, ...